Governance Prime Medicine, Inc.

PRME

US74168J1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 06:00:00 14/05/26 am AEST			5-day change	1st Jan Change
3.270 ^USD	-0.91%		-4.11%	-5.76%

08/05	Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
17/04	Prime Medicine, Inc. Appoints Svetlana Makhni as Chief Financial Officer	CI

Executive Committee: Prime Medicine, Inc.

Manager

Positions heldSince

Allan Reine

51 year

Chief Executive Officer

19/05/2025

Gregory Dearborn

Investor Relations Contact

Fubao Wang

General Counsel

01/05/2022

Karen Brown

General Counsel

01/04/2021

Niamh Alix

Human Resources Officer

01/06/2022

Meredith Goldwasser

54 year

Chief Operating Officer

01/09/2022

Ann Lee

64 year

Chief Tech/Sci/R&D Officer

01/10/2021

Carman Alenson

60 year

Comptroller/Controller/Auditor

01/08/2021

Svetlana Makhni

42 year

Director of Finance/CFO

16/04/2026

Composition of the Board of Directors: Prime Medicine, Inc.

Director

CommitteesSince

Jeffrey Marrazzo

48 year

Chairman

19/05/2025

Michael Kelly

69 year

Audit Committee Chair
Finance Committee Chair	15/07/2020
Governance Committee
Nominating Committee
Compensation Committee Chair	16/10/2024

David Schenkein

68 year

Governance Committee	01/05/2015
Nominating Committee	01/05/2015
Compensation Committee	08/09/2023
Governance Committee Chair
Nominating Committee Chair

Kaye Foster-Cheek

66 year

Compensation Committee	24/05/2023
HR Committee	24/05/2023
Governance Committee Chair	09/12/2014
Nominating Committee Chair	09/12/2014
Compensation Committee Chair

Wendy Chung

57 year

Governance Committee
Nominating Committee
Audit Committee

Thomas Cahill

39 year

Audit Committee
Governance Committee
Nominating Committee

Robert Nelsen

62 year

Nominating Committee Chair	23/04/2010
Compensation Committee

Allan Reine

51 year

Audit Committee Chair

23/03/2022

Latest Appointments: Prime Medicine, Inc.

16/04	Prime Medicine, Inc. Announces Executive Changes, Effective April 16, 2026	CI
04/11	Prime Medicine, Inc. Appoints Matthew Hawryluk as Chief Business Officer	CI
30/09/25	Septerna Appoints Keith Gottesdiener to Its Board of Directors and as Chairperson of R&D Committee of the Board and to the as A Member of the Compensation Committee of the Board	CI
16/07/25	Prime Medicine, Inc. Announces Step Down of Jeremy Duffield as Chief Scientific Officer, Effective July 15, 2025	CI
19/05/25	Prime Medicine to Cut Costs, Focus on Liver Treatment Programs; New CEO Named	MT
19/05/25	Prime Medicine Announces Strategic Restructuring To Focus On Opportunities In Large Genetic Liver Diseases, Cystic Fibrosis, And Partnered Programs Alongside CEO Leadership Transition	RE
19/05/25	Prime Medicine, Inc. Announces CEO Changes	CI

More news

Former Officers and Directors: Prime Medicine, Inc.

Insider

Positions held

SinceUntil

Jeremy Duffield

Chief Tech/Sci/R&D Officer

01/01/2021

15/07/2025

Keith Gottesdiener

Director/Board Member	01/07/2020	18/05/2025
Chief Executive Officer	01/07/2020	18/05/2025
President	01/07/2020	18/05/2025

Stephen Knight

Director/Board Member

13/09/2019

22/09/2022

John Evans

Director/Board Member

13/09/2019

13/09/2022

David Liu

Founder

Mohammed Asmal

Chief Tech/Sci/R&D Officer

Age distribution of managers

Parity Men Women

Male	15
Female	4

Of which Executive Committee

Male	6
Female	3

Of which Directors

Male	7
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its gene editing technology enables targeted modifications to genomic deoxyribonucleic acid (DNA) without introducing double-stranded breaks. The Company pipeline includes wholly owned in vivo programs targeting liver genetic diseases Wilson Disease, Alpha-1 Antitrypsin Deficiency (AATD) as well as early-stage discovery efforts in Cystic Fibrosis (CF). The PM359 is an ex vivo prime editing program designed to correct the GT mutation in the NCF1 gene, the most common cause of Chronic Granulomatous Disease (CGD). This program provides validation of prime editing in human cells. The Wilson Disease is a rare autosomal recessive disorder caused by loss-of-function mutations in ATP7B.

Employees

146

Sector

Biotechnology & Medical Research

More about the company